DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Ribas A, Puzanov I, Dummer R. et al.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial.
Lancet Oncol 2015;
16: 908-918
We do not assume any responsibility for the contents of the web pages of other providers.